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Abstract 
Objective: To compare procedure duration, complications, and acceptability of dilation and 
evacuation (D&E) with and without feticide by intra-cardiac potassium chloride (KCL) 
injection.  
Study design: We evaluated outcomes with D&E at 18-24 weeks’ gestation in the 6 months 
before and 6 months after removing feticide with KCL from the guidelines of a national 
British abortion provider.  We extracted demographic and procedure-related data from 
medical records and electronic databases. We surveyed women undergoing D&E in both 
time periods about acceptability and side effects. 
Results: We analyzed 291 cases with and 257 cases without KCL. Unadjusted mean 
procedure duration was shorter with KCL than without (12.7 vs. 16.1 minutes, respectively, 
p<0.001).  After adjustment for age, parity, Cesarean deliveries, gestational age, body mass 
index, surgeon, and number or duration of osmotic dilators used, KCL remained associated 
with a 3.5 minute (95% CI 2.4-4.6) reduction in D&E duration. Uterine atony was more 
common with KCL than without (3% vs. 0%, respectively, P<0.001), despite more frequent 
administration of prophylactic utero-tonics to women who received KCL (82% KCL vs. 73% 
no-KCL, p=0.001). Women who had KCL reported more pain in the period between feticide 
and dilator placement and the evacuation than women who had not received feticide (49% 
vs. 25%, respectively, p<0.001). Most women in both groups found their procedure very 
acceptable or acceptable (79% KCL vs. 87% no-KCL, p=0.2). 
Conclusions: Feticide with intra-cardiac KCL reduced D&E procedure duration, but was 
associated with more pain and uterine atony. Treatment acceptability was high with and 
without feticide. 
Implications:  Inducing fetal demise before dilation and evacuation with intra-cardiac 
potassium chloride may result in shorter operative times but does not improve safety or 
acceptability. Level I evidence remains needed to support the use of feticide before surgical 
abortion. 
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Introduction  
Fetal demise is induced before dilation and evacuation (D&E) by some abortion providers in 
the belief that it facilitates an easier, faster and safer evacuation [1]. Other frequently cited 
reasons for this practice are patient preference [2,3], avoiding prosecution [4], and avoiding 
extramural delivery with signs of life [1,5].   
The most commonly used methods of inducing fetal demise before a D&E are intra-amniotic 
or intra-fetal injection of digoxin, and fetal intra-cardiac potassium chloride (KCL) injection 
[1]. Research is limited, but the few existing comparative studies suggest that these methods 
do not confer a clinical benefit and may increase risks.  A randomized controlled trial of intra-
amniotic digoxin injection found no reduction in D&E procedure duration, difficulty, or blood 
loss compared to placebo, but an increased risk of vomiting [2]. Extramural delivery, 
hospitalization, and signs of infection have also been reported as more frequent with digoxin 
use before D&E than with non-use [6].  The only comparative study of feticide with intra-
cardiac KCL is a retrospective review of D&Es performed after KCL (n=23), without feticide 
(n=53), and for spontaneous fetal demise (n=52) [7]. Feticide with intra-cardiac KCL did not 
reduce anesthesia (operative) time or blood loss but was associated with a higher risk of 
cervical laceration. Although complications with the administration of fetal intra-cardiac KCL 
are rare [8, 9] chorioamnionitis has been reported with its use in the setting of selective fetal 
reduction [10] and one case report of maternal cardiac arrest due to inadvertent 
intravascular injection has been published [11].    
British Pregnancy Advisory Service (BPAS) is a non-profit abortion provider with clinics in 
England, Scotland and Wales. The organization performs approximately 60,000 abortions 
annually of which over 1,800 are D&Es between 18 and 24 weeks’ gestation. Since 2004, 
the BPAS guidelines have stipulated feticide with KCL as standard practice before surgical 
abortions performed at 22-23+6 weeks’ gestation. In 2008, the criteria for feticide were 
expanded to also include pregnancies at 18-21+6 weeks’ gestation when coupled with one 
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or more of the following characteristics: age ≤18 years, or body mass index (BMI) ≥33, or ≥2 
Cesarean deliveries.  
The BPAS Clinical Governance Committee reconsidered the inclusion of feticide in the 
organization’s D&E guidance following the publication of research suggesting that the risks 
with feticide outweigh the benefits, and the conclusion in US guidelines [1, 12] that there is 
insufficient evidence to recommend feticide to increase the safety of D&E. The committee 
decided to remove feticide from the BPAS guidelines on D&E but wished to actively monitor 
the impact of this change in longstanding practice. This paper reports on the findings of that 
evaluation which spanned the 6 months prior to and the 6 months after the guideline 
changed. 
 
Materials and methods  
We conducted an evaluation at the three BPAS clinics in England where D&E with KCL was 
performed. To allow an even number of months for each cohort, we reviewed routinely 
collected data from all D&Es with KCL in the 6 months before its removal from organizational 
guidance and for all D&Es that would have met criteria for KCL in the 6 months after its 
removal.  The criteria for feticide were 1) gestational age of 22-23+6 weeks, or 2) gestational 
age of 18-21+6 weeks combined with one or more of the following characteristics: age ≤18 
years, or body mass index (BMI) ≥33, or ≥2 Cesarean deliveries. The nurse undertaking the 
abortion consultation provided women with written and verbal information about the 
evaluation and obtained consent for the treatment to be provided. All BPAS clients receive 
written information about how their anonymized data may be accessed for use, including 
service evaluations and research.  
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From February-July 2014, a fetal intra-cardiac KCL injection followed by insertion of osmotic 
cervical dilators was performed the day prior to evacuation (Day 1). Using ultrasound, the 
surgeon confirmed correct placement of a 16-cm 17-gauge Chiba needle (Cook Ob/Gyn, IN, 
USA) in the fetal ventricle and injected 1-3 ml of a 15% KCL solution. If asystole was not 
observed, the surgeon gave further doses of KCL. Immediately after the injection, the 
surgeon inserted Dilapan osmotic cervical dilators (4mm x 65mm). The number of dilators to 
be inserted was not stipulated in BPAS’ guidance. Antibiotic prophylaxis with azithromycin 
one gram orally once or doxycycline 100 mg orally twice per day for seven days was 
administered following feticide and dilator insertion [5].  
 
Women were discharged and returned the next day for evacuation (Day 2). Adjunctive 
misoprostol was administered after admission to the clinic. The recommended regime for 
adjunctive misoprostol was misoprostol 400 mcg vaginally for 3 hours or sublingually for 2 
hours. In cases of inadequate dilation, women received additional doses of misoprostol 
and/or osmotic dilators for 3 more hours. If the surgeon determined the dilation was 
insufficient to safely complete the procedure, additional dilators were placed for another 24 
hours and the evacuation performed on Day 3.  
 
Evacuations were undertaken under general anesthesia with propofol and fentanyl, without 
intubation. Additional antibiotic prophylaxis with metronidazole one gram per rectum was 
administered immediately post-operatively [5]. The use of prophylactic or indicated utero-
tonics was left to the discretion of the surgeon. Eight experienced providers performed all 
procedures, of which six performed most of the evacuations across both time periods; one 
provider performed 3 procedures with KCL and none without KCL and one performed 3 
procedures without KCL and none with KCL. 
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From August 2014-January 2015, the use of feticide was removed from organizational D&E 
guidelines. Those women who would have previously met criteria for feticide had Dilapan 
placed on Day 1 while awake. Cervical anesthesia was not used for insertion. All other 
procedures were performed as described.  
 
We extracted demographic data and data on procedures and complications from the case 
note onto a data collection form. Procedure start and end times were recorded by a health 
care assistant from a clock in the theater and reflect the time from the first instrument 
inserted into the vagina to the last instrument removed from the vagina. The times were 
recorded in hours and minutes. A nurse administered surveys about nausea, vomiting, pain, 
and cramping between feticide and/or dilator placement and the evacuation, and asked 
women to rank the severity and/or frequency of their symptoms. Women were also asked to 
rank the acceptability of the procedure they underwent (feticide and Dilapan insertion or 
Dilapan insertion alone) using a 5-point Likert scale. The nurse aimed to survey clients prior 
to the evacuation but in some cases the surveys were performed after the evacuation.  
 
The primary outcomes were the duration of the D&E and ‘any complication’. Complications 
were limited to those occurring at the time of the procedure. Complications were reported by 
the surgeon or a member of the theater team on incident reporting forms and coded using 
the organization’s existing codes for incidents. The codes also indicated if the complication 
was major or minor. Major complications were: uterine perforation, hemorrhage (estimated 
blood loss ≥ 500 ml) requiring transfusion, uterine atony requiring more than one dose of 
utero-tonic medication or an additional intervention (e.g., uterine massage) or both, infection 
requiring hospitalization, exploratory laparoscopy or laparotomy, hysterectomy, pulmonary 
aspiration, adverse drug reaction requiring hospitalization, extramural delivery, and failed 
procedure. Minor complications were: cervical false passage, cervical laceration requiring 
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repair, hemorrhage not requiring transfusion, uterine atony not requiring more than one dose 
of uterotonic medication or additional intervention, incomplete abortion, hematometra, 
infection not requiring hospitalization, vasovagal reaction, and adverse drug reaction not 
requiring hospitalization. 
 
We generated descriptive statistics overall and by group (KCL and no-KCL). We used Chi-
square, Fisher’s Exact, Student’s t, Wilcoxon rank sum, and Anova tests to assess 
differences by group in bivariate analyses. We used multivariable linear regression to assess 
the relationship between procedure duration and KCL, adjusted for other variables. We 
defined statistical significance as a two-tailed p-value of ≤0.05. Data were analyzed using 
STATA Statistical Software, release 13.0 (Stata-Corp., College Station, TX). 
 
This project was approved by BPAS’ Research and Ethics Committee (Ref. 2014/01/PL).  
 
Results 
Five-hundred forty-eight women were involved in the evaluation: 291 (53.1%) received 
feticide with KCL before their D&E and 257 (46.9%) did not receive feticide. Demographic 
characteristics, obstetrical history, body mass index (BMI), and gestational age were not 
different between groups (Table 1). Most women were nulliparous (66.6%). Of those who 
were parous, 19.1% (n=36) had one or more prior Cesarean deliveries (18 per group). The 
mean gestational age in both groups was 22 weeks and 2 days. All but two of the 
pregnancies were singleton gestations.  
We excluded five women from the analysis of outcomes. Three women in the KCL group did 
not return to the clinic for evacuation. In two cases, the women informed the clinic staff that 
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they were unable to arrange or afford transportation. One of them presented to a local 
hospital two days later and delivered spontaneously. An induction of labor in a local hospital 
was organized for the second woman. In the third case, clinic staff members were unable to 
contact the woman to ascertain her reasons for not returning. The clinic was then contacted 
by a hospital consultant several weeks later when she presented in labor and delivered the 
demised fetus. Two women in the no-KCL group did not progress to a surgical evacuation. 
One chose to continue the pregnancy and had the Dilapan removed. The other was deemed 
unsuitable for general anesthesia on Day 2 because of a chest infection. She had a medical 
induction in hospital.  
 
Procedure details are summarized in Table 2. Feticide with intra-cardiac KCL was 
administered under general anesthesia with propofol and fentanyl without intubation in 98% 
of cases. Local anesthesia was used in the remaining 2%.  The mean volume of KCL 
administered was 6.2 ml (range 1.5-10 ml) and median length of time to complete the 
feticidal procedure and insert Dilapan was 8 minutes (range 5-28 minutes).  Cervical 
preparation was undertaken with Dilapan in all cases, but fewer were placed when KCL was 
used. When KCL was administered, 0.3% (n=1) of women had 2 Dilapan inserted, 93.8% 
(n=273) received 3 Dilapan, and 5.8% (n=17) had 4 or more placed. In the period when KCL 
was omitted, 1.6% (n=4) had 2 Dilapan, 57.2% (n=147) had 3, and 41.2% (n=106) had 4 or 
more inserted. The duration of time that the Dilapan were left in situ was shorter with KCL 
than without KCL (mean 22.8 vs. 24.1 hours, respectively, p<0.001). Adjunctive misoprostol 
was used in 99% (n=287) of women in the KCL group and 100% in the no-KCL group 
(p=0.1). Most women (98.7%) received misoprostol 400 mcg vaginally for 3 hours (62.0%) or 
sublingually for 2 hours (36.5%) pre-operatively. There was no significant difference in the 
dose, route or duration of adjunctive misoprostol between groups. There was no difference 
between groups in the number of women who required an additional set of Dilapan (3 KCL 
vs. 1 no-KCL, p=0.4), additional misoprostol (3 KCL vs. 3 no-KCL, p=0.8), Dilapan insertion 
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over two days (2 KCL vs. 0 no-KCL, p=0.5), or need for additional dilation intra-operatively 
(21 KCL vs. 17 no-KCL, p=0.5). The proportion of procedures with and without KCL and total 
number of procedures performed was similar across the clinical sites. Each surgeon 
performed similar proportions of procedures with and without KCL.  
 
Mean procedure duration was significantly shorter in the KCL group compared to the no-KCL 
group (12.7 vs. 16.1 minutes, p<0.001). Median procedure duration was 11 minutes (range: 
3-34) with KCL and 15 minutes (range: 5-56) without KCL (p<0.001). Other variables 
significantly associated with a reduction in procedure duration in bivariate analyses were 
surgeon, gestational age less than 22 weeks’, and a greater number of Dilapan placed (all 
p<0.001; data not shown). Factors not associated with a reduction in procedure duration in 
bivariate analysis were age, parity, prior Cesarean deliveries, BMI or duration of Dilapan in 
situ (data not shown). In multivariable linear regression (Table 3), KCL was independently 
associated with a decrease in procedure duration of 3.5 minutes (95% CI 2.4-4.6). Other 
variables of interest significantly associated with a reduction in procedure duration were 
longer duration of Dilapan in situ, lower gestational age, and fewer Caesarean deliveries. 
Age, parity, BMI, and number of Dilapan were not associated with procedure duration. 
 
There was no significant difference in overall complications between groups (7.3% KCL vs. 
4.3% no-KCL, p=0.1) (Table 4). Five women had major complications in the KCL group 
compared to 4 in the no-KCL group (1.7% vs. 1.6%, respectively, p=0.9). In the KCL group, 
these were 3 extramural deliveries following administration of adjunctive misoprostol, one 
case of major atony, and one hemorrhage resulting in disseminated intravascular 
coagulopathy, hysterectomy and uterine artery embolization in a woman with abnormal 
placentation. In the no-KCL group, major complications were two extramural deliveries, one 
case of major atony, and two failed procedures. In one of the procedure failures, the cervix 
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was displaced due to fecal impaction and could not be reached by the surgeon. The client 
had a medical induction. In the other failed procedure, the surgeon was only able to partially 
complete the evacuation due to high and transverse fetal lie. Misoprostol and oxytocin were 
administered to bring the fetal parts into the lower part of uterus to facilitate extraction. An 
extramural delivery followed shortly after their initiation. The other extramural delivery 
occurred in the clinic after placement of a second set of Dilapan.  
 
Total minor complications were not significantly different between groups (5.6% KCL vs. 
3.1% no-KCL, p=0.2). However, there were significantly more cases of minor atony with KCL 
than without KCL (3.1% vs. 0%, respectively, p=0.004). This was despite appreciably more 
women in the KCL group receiving prophylactic utero-tonics (81.6% KCL vs. 72.6% no-KCL, 
p=0.01). There was no difference in hemorrhage or need for transfusion between groups. 
More women in the no-KCL group had cervical lacerations requiring repair, but this was not 
significant (2.8% no-KCL vs. 0.7% KCL, p=0.06, OR 4.0, 95% CI 0.8-19.7). Neither KCL nor 
any of the other variables of interest (i.e., clinic, surgeon, age, BMI, prior Cesareans, 
gestational age, or number or duration of Dilapan in situ) were associated with “any 
complication” in bivariate analysis (data not shown). 
 
Information about side effects and acceptability was provided by 538 women (Table 5). In 
92.5% of cases (n=481), feedback was received just prior to the evacuation and in 7.5% 
(n=39) after the evacuation. More women who received KCL reported nausea than women 
who did not have KCL (31.0% vs. 18.5%, respectively, p=0.001). Most women in the KCL 
group who had nausea reported it as mild (64.2%). Vomiting was not different between 
groups (18.8% KCL vs. 18.5% no-KCL, p=0.9). Pain was more frequently reported by 
women who had undergone feticide (49% KCL vs. 24.5% no-KCL, p=<0.001), mainly at the 
KCL injection site. There was no difference in cramping overnight (55.9% KCL vs. 59.7% no-
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KCL, p=0.4). The proportion of women who rated their procedure as acceptable or very 
acceptable did not differ between groups (79.4% KCL vs. 87.0% no-KCL, p=0.2). The overall 
pattern of responses for side effects remained the same overall and stratified by timing of 
survey. Reported levels of nausea, vomiting, and pain were higher in the KCL group when 
the surveys were performed post-procedure but these were not statistically significantly 
different due to the small numbers of surveys done at this time.  
 
Discussion 
In this comparative service evaluation, we found that injection of fetal intra-cardiac KCL prior 
to D&E at 18-24 weeks’ gestation was associated with a reduction in procedure duration of 
3.5 minutes (95% CI 2.4-4.6) after adjustment for age, parity, Cesarean deliveries, gestation, 
BMI, surgeon, and number and duration of Dilapan in situ. Feticide with KCL was also 
associated with more reported nausea, pain at the injection site, and uterine atony. The 
KCL-associated reduction in procedure duration we observed was independent of other 
factors that also led to modest duration reductions (i.e., longer duration of Dilapan in situ) or 
of those that increased procedure duration (i.e., more Cesareans, greater gestational age).  
These findings contrast with those of Jackson et. al, [2] who found no difference in 
procedure duration between intra-amniotic digoxin and a placebo injection, even within 
subgroupings by gestation, surgeon and parity. One potential explanation for this difference 
in findings is that the duration of fetal demise, and opportunity for subsequent softening of 
the fetal tissues and cervical ripening, is longer with KCL than digoxin. Potassium chloride 
induces asystole immediately compared to intra-amniotic digoxin, which can take 4 hours or 
more to cause fetal demise [13]. Intra-amniotic digoxin may also fail to induce demise in up 
to 8% of cases [1]. This may not be comparable when digoxin is administered intra-fetally, 
including into the fetal heart, however, which may lead to faster and/or immediate induction 
of demise. Alternatively it may be that the intense vasoconstriction known to be induced by 
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high concentrations of KCL directly damages fetal tissues accelerating autolysis which 
facilitates the evacuation.   
 
Our findings also differ from those in the small retrospective analysis by Singh et. al, [7] who 
found no reduction in procedure times when comparing D&Es with and without KCL or 
spontaneous demise One possible explanation for the increased operative time without KCL 
that we observed is that the surgeons, who had been performing D&E with KCL for many 
years, were unaccustomed to the feel of fetal tissue at advanced gestations without KCL. It 
is possible that, with time, their operative times would have decreased as they became used 
to approaching the cases in a way suited to less fetal maceration.  
 
Complications were infrequent, and we found no difference in the overall number of cases 
with any complication, or in major or minor subgroupings with and without KCL. Neither 
extramural deliveries nor infection were higher with KCL than without KCL. Uterine atony 
requiring massage or administration of a single utero-tonic agent was significantly more 
common with KCL, despite more women in this group receiving prophylactic utero-tonics. 
We are uncertain as to the reason for this finding. Although atony can be a very serious 
complication, there was no difference between groups in atony needing multiple 
interventions, hemorrhage or blood transfusions, potentially due to prophylactic 
interventions.  
 
We documented that women receiving KCL reported more nausea. This side effect was 
most likely due to the fentanyl administered as part of the general anesthesia regimen used 
for the feticidal injection. Feticide with intra-cardiac KCL can be administered with local 
anesthesia [8], which may have reduced this side effect as well as the injection site pain that 
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women reported.  It is also notable that in all cases, the duration of time necessary to 
perform the feticidal injection exceeded the observed reduction in D&E procedure duration in 
all cases. Despite differences in discomfort and substantial differences in process, overall 
acceptability of treatment was high in both, and not different between, groups.  
 
The main limitation of this evaluation is that it was not a randomized trial.  We are, therefore, 
unable to state conclusively that KCL would influence outcomes with D&E differently from 
not using KCL if women were allocated at random. Although not randomized, we benefitted 
from a large sample and the groups were very similar, and particularly with regard to 
characteristics such as gestational age, multiple prior Cesareans and higher BMI, which 
have been shown to affect procedure duration or complications in other studies of D&E [16, 
17, 18]. In addition, procedural variations introduced by surgeons when KCL was removed 
from organizational guidelines, such as using more Dilapan and leaving them in place 
longer, did not reduce procedure duration to the same degree as KCL administration. This 
suggests that the observed effect of KCL might have been greater had those variations not 
been introduced.  
In conclusion, we found that feticide with intra-cardiac KCL is associated with a reduction in 
D&E procedure duration but with more reported pain, mainly at the injection site, and an 
increased occurrence of uterine atony. A randomized trial is necessary to confirm these 
results. Even if a reduction in D&E duration is demonstrable in a trial, this additional 
efficiency at the time of evacuation needs to be weighed against the need to provide 
advanced training to clinicians in safe and effective ultra-sound guided intra-fetal intra-
cardiac injections, risks associated with the injection including those of sedation or general 
anesthesia if needed for administration, and the time necessary to perform the feticide 
injection.  
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Table 1. Baseline characteristics of women who underwent dilation and evacuation with and without 
feticide with potassium chloride (KCL) from February 2014-January 2015 at British Pregnancy 
Advisory Service (N=548) 
Characteristic  
            KCL* 
(n=291) 
No-KCL** 
(n=257) p-value
 
Demographics    
Age in years 22.4 ± 6.8 22.8 ± 6.8 0.7
 
 Age range 
 
11-46 13-44  
Ethnicity   0.5 
 White  242 (82.9) 204 (79.7)  
 Mixed 12 (4.1) 10 (3.9)  
 Asian/Asian British 16 (5.5) 14 (5.5)  
 Black/Black British 19 (6.5) 26 (10.2)  
 Chinese/Other 2 (0.7) 0  
 Missing data 1 (0.3) 2 (0.8)  
Relationship status   0.6 
 Single 140 (48.1) 110 (42.9)  
 Partnered, not married 115 (39.5) 109 (42.4)  
 Married 25 (8.6) 23 (8.6)  
 Divorced/separated/widowed 8 (2.8) 9 (3.5)  
 Did not disclose 3 (1.0) 6 (2.3)  
Body Mass Index (kg/m
2
)***    
 ≤33 275 (94.5) 242 (94.1) 0.9 
 >33 16 (5.5) 15 (5.8)  
Reproductive History    
Parity   0.4 
 0 199 (68.2) 166 (64.8)  
 1+ 93 (31.9) 90 (35.2)  
Vaginal deliveries   0.4 
 0 214 (73.5) 180 (70.0)  
 1+ 77 (26.5) 77 (30.0)  
Caesarean deliveries   0.9 
 1 8 (2.8) 11 (4.3)  
 2+ 10 (3.4) 7 (3.9)  
Prior abortion 55 (18.9) 52 (20.2) 0.2 
Current Pregnancy    
Gestational age in weeks + days 22+2 ± 1+3 22+2 ± 1+4 0.9 
Gestational age range  18+0-24+0 17+0-23+6  
Gestation   0.2 
 Singleton 289 (99.3) 257 (100)  
 Twin 2 (0.7) 0  
     
Data presented as n (%) or mean ± standard deviation, unless otherwise noted 
* KCL = feticide with intra-cardiac potassium chloride 
** No-KCL= no feticide  
***Indications for feticide from 18+0 and 21+6 weeks’ gestation include BMI over 33 kg/m2 
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Table 2. Details of feticidal and dilation and evacuation procedures performed with and 
without feticide with potassium chloride (KCL) from February 2014-January 2015 at British 
Pregnancy Advisory Service (N=548) 
 KCL* 
N=291 
No KCL** 
N=257 
p-value 
Distribution of feticidal procedures by 
clinical site 
   
    1  93 (31.9) - - 
    2  106 (36.4) - - 
    3  92 (31.6) - - 
Distribution of feticidal procedures by 
surgeon 
   
    1 49 (16.8) - - 
    2 21 (7.2) - - 
    3 83 (28.5) - - 
    5 26 (8.9) - - 
    7 87 (29.9) - - 
    9 24 (8.3) - - 
    10 1 (0.3) -  
Feticide anesthesia    
    General 285 (97.9) - - 
    Local 6 (2.1) - - 
KCL dose in ml 6.2 ± 2.7 - - 
KCL dose range  1.5-10   
    
Median feticide procedure duration in 
minutes (range) 
8 (5-28) - - 
Cervical preparation    
Number of Dilapan placed (first set)   <0.001 
        2 1 (0.3) 4 (1.6)  
        3 273 (93.8) 147 (57.2)  
        4+ 17 (5.8) 106 (41.2)  
Number Dilapan (first set) by gestational 
age group 
   
        <22 weeks’ gestation 3.0 ± 0.3 3.4 ± 0.6 <0.001 
        ≥ 22 weeks’ gestation 3.1 ± 0.4 3.5 ± 0.7 <0.001 
Adjunctive misoprostol   0.3 
        Yes 287 (99.6) 255 (100) 
        No 1 (0.4) 0  
Adjunctive misoprostol dose (mcg)   0.2 
        400 285 (99.3) 255 (100)  
        600 2 (0.7) 0  
Adjunctive misoprostol route   0.2 
        Vaginal  189 (65.9) 150 (58.8)  
        Oral 1 (0.4) 2 (0.8) 
        Sublingual 97 (33.8) 103 (40.4) 
Length of time misoprostol to procedure 
in hours 
3.4 ± 2.6 3.1 ± 0.8 0.06 
Duration Dilapan in situ (first set)  22.9 ± 3.6 24.1 ± 2.2 <0.001 
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Number receiving second set of Dilapan  3 (1.0) 1 (0.4) 0.4 
Number receiving second dose of 
misoprostol 
3 (1.0) 3 (1.2) 0.8 
Mechanical dilatation required    0.8 
    Yes 21 (7.3) 17 (6.7)  
    No 262 (91.0) 235 (92.2)  
    Not documented 5 (1.7) 3 (1.2)  
Distribution of evacuations by clinical 
site 
  0.6 
    1  92 (31.9) 90 (35.3)  
    2  103 (35.8) 92 (36.1)  
    3  93 (32.3) 73 (28.6)  
Distribution of evacuations by 
surgeon
§
 
  <0.001 
    1 51 (17.7) 41 (16.1)  
    2 3 (1.0) 13 (5.1)  
    3 96 (33.3) 79 (31.0)  
    4 49 (17.0) 38 (14.9)  
    5 75 (26.0) 52 (20.4)  
    6 11 (3.8) 29 (11.4)  
    7 3 (1.0) 0  
    8 0 3 (1.2)  
Evacuation duration in minutes  12.7 ± 5.0 
 
16.1 ± 7.9 <0.001 
Median evacuation duration in 
minutes (IQR) (range) 
11 (10-15)  
(3-34) 
15 (11-19) 
(5-56) 
 
<0.001 
 
Data presented as n (%) or mean ± standard deviation, unless otherwise noted 
* KCL = feticide with intra-cardiac potassium chloride 
** No-KCL= no feticide  
§
n=288 for KCL group as three women did not return to BPAS for the evacuation, n=255 for no-KCL 
group as two women did not progress to surgical evacuation 
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Table 3. Multivariable linear regression of variables associated with dilation and evacuation 
procedure duration in women who underwent dilation and evacuation with and without feticide with 
potassium chloride (KCL) from February 2014-January 2015 at British Pregnancy Advisory Service 
(N=543) 
Variable of interest  Effect on 
procedure  
duration in 
minutes 
95% Confidence 
Interval 
p-
value 
KCL* vs. no-KCL** -3.49 -4.61, -2.37 <0.001 
Age > 18 years vs. ≤ 18 years -1.21 -2.46, 0.03 0.06 
BMI*** ≥ 33 kg/m2 vs. < 33 kg/m2 0.11 -2.13, 2.35 0.92 
Parous vs. Nulliparous -0.60 -1.83, 0.64 0.34 
Gestational age < 22 vs. ≥ 22 weeks  -4.60 -5.85, -3.35 <0.001 
Prior Cesarean delivery ≤ 1 vs. ≥ 2 -4.21 -7.28, -1.15 0.007 
Increased time Dilapan in situ 
(continuous variable in hours) 
-0.28 -0.50, -0.07 0.01 
Increased number Dilapan in situ 
(continuous variable) 
0.79 -0.12, 1.69 0.09 
Surgeon performing evacuation    
          1 Reference - - 
          2 -2.94 -6.02, 0.14 0.06 
          3 -2.38 -3.89, -0.87 0.002 
          5 -6.19 -7.91, -4.47 <0.001 
          6 -6.21 -7.86, -4.58 <0.001 
          7 -4.22 -6.45, -1.98 <0.001 
         9 -6.35 -13, 0.30 0.06 
         10 -0.79 -7.47, 5.89 0.82 
* KCL = feticide with intra-cardiac potassium chloride 
** No-KCL= no feticide  
*** BMI =Body Mass Index 
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Table 4: Overall, major and minor complications in women who underwent dilation and evacuation 
with and without feticide with potassium chloride (KCL) from February 2014-January 2015 at British 
Pregnancy Advisory Service (N=543) 
 KCL* 
(N=288) 
No-
KCL** 
(N=255) 
p-value 
Procedures with any complication  21 (7.3) 11 (4.3) 0.1 
Major complications  5 (1.7) 4 (1.6) 0.9 
Extramural delivery  3 (1.0) 2 (0.8) 0.7 
Major atony*** 1 (0.3) 1 (0.4) 0.9 
Hemorrhage
¥
 requiring transfusion  1 (0.4)  0 0.3 
Failed procedure  0 2 (0.8) 0.1 
Disseminated intravascular coagulopathy 1 (0.4) 0 0.3 
Minor complications 16 (5.6) 8 (3.1) 0.2 
Cervical laceration requiring repair  2 (0.7) 7 (2.8) 0.06 
Adverse drug reaction  1 (0.4) 0 0.3 
Minor atony
§
 9 (3.1) 0 0.004 
Hemorrhage not requiring transfusion  4 (1.4) 2 (0.8) 0.5 
* KCL = feticide with intra-cardiac potassium chloride 
** No-KCL= no feticide  
*** Requiring more than one dose of utero-tonic medication or an additional intervention or both 
¥
Hemorrhage defined as estimated blood loss ≥ 500 ml 
§
Not requiring more than one dose of uterotonic medication or additional intervention 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
D&E with and without feticide 
 
22 
 
Table 5. Reported overnight side effects and acceptability of procedure in women who underwent 
dilation and evacuation with and without feticide with potassium chloride (KCL) from February 2014-
January 2015 at British Pregnancy Advisory Service (N=538) 
 
 KCL* 
(n=286) 
No-KCL** 
(n=252) 
p-value 
Any nausea 81 (31.0) 43 (18.5) 0.001 
Nausea rating   0.1 
Mild 52 (64.2) 21 (48.8)  
Moderate 20 (24.7) 18 (41.9) 
Severe 9 (11.1) 4 (9.3) 
Any vomiting 49 (18.8) 43 (18.5) 0.9 
Number of vomiting episodes 2 (1-10) 2.4 (1-12) 0.4 
Vomiting rating   0.007 
Mild 29 (59.2) 17 (39.5)  
Moderate 11 (22.5) 23 (53.5) 
Severe 9 (18.4) 3 (6.9) 
Any pain 128 (49.0) 57 (24.5) <0.001 
Pain rating   0.3 
Mild 72 (56.3) 29 (50.9)  
Moderate 47 (36.7) 20 (35.1) 
Severe 9 (7.0) 8 (14.0) 
Any cramping 146 (55.9) 139 (59.7) 0.4 
Cramping rating   0.9 
Mild 104 (72.2) 98 (70.5)  
Moderate 33 (22.9) 35 (25.2) 
Severe 7 (4.9) 6 (4.3) 
How acceptable did you find the procedure?   0.2 
Very acceptable 34 (14.3) 33 (14.3)  
Acceptable 155 (65.1) 168 (72.7) 
Neither acceptable nor unacceptable 40 (16.8) 25 (10.8) 
Unacceptable 8 (3.4) 5 (2.7) 
Very unacceptable 1 (0.4) 0 
 
* KCL = feticide with intra-cardiac potassium chloride 
** No-KCL= no feticide  
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